The study by Kailash Thapaliya, PhD, reveals a notable increase in glucagon-like peptide-1 receptor agonist (GLP-1 RA) prescriptions among Australian women aged 18 to 49 from 2011 to 2022, especially in those without type 2 diabetes. Among approximately 1.6 million women, 1% were prescribed GLP-1 RAs, with a significant rise in incidence noted, particularly in patients without diabetes. Only 21% were using contraception at initiation, raising concerns about unintended pregnancies, highlighting the need for better guidance on safe prescribing in this demographic.

Source: The Medical Journal of Australia